Zosano Pharma, which is developing a transdermal formulation of an approved osteoporosis treatment, raised $50 million on Tuesday by offering 4.5 million shares (upsized from 4.3 million shares) at $11, the midpoint of the range of $10 to $12. The day before, the company had filed to increase the number of shares offered from 3.0 million to 4.3 million, increasing the proposed deal size 43%. Zosano Pharma trades on the NASDAQ under the symbol ZSAN. Zosano Pharma initially filed confidentially on 5/13/2014. Ladenburg Thalmann & Co. and Roth Capital acted as lead managers on the deal.
